Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL..Everyone not already in...
We all like to think that...but if we were our name would be DART.
The stock market has little rationale, we are the minions, fundamentals are the one true measure of a companies worth.
Those that swear by charts, fall prey to "any" catalyst that may occur at any given moment, charts are more of a prediction of what may occur, unfortunately their are millions of things that can happen in the market each day to throw the charts into disarray.
TPIV has been so undervalued for so long, it should at this point in time have a 200/300 million dollar valuation...that just goes to show the irrational of the market.
Just like KITE and JUNO have billion dollar valuations and their science is not much farther along than ours, and ours seems to be vastly superior.
Wishing you the best in your trading, I'm more of a BUFFETT disciple myself, don't want to give the "Tax man" any more than I have too.
Blu
Like I said .49.
Be careful that logic may leave you out in the cold on this one, too many massive reasons, unlike other stocks. When this takes off it's gone for good.
Dart most likely will hold most of his shares, to get this up into NASDAQ territory...if he's holding, demand will far and away outpace any other selling, and I presume that will be his goal going into initiation of PHASE 11, .
All of a sudden $2, $3, $4 may not be so far out of the question, especially with all the 3 to 6 month catalyst's.
Blu
Conference was great...
Key that makes this a monster..."LOW COST', "LOW COST", "LOW COST" easily injectable, at Doctors office or even at home, we will be courted by everyone after PHASE 11 starts.
Glynn mentioned once again about a partner, collaborator, anyone see milestone payments in our future.
Will be under 100 mill out, $10 buyout/acquisition minimum, unless the market takes us past there in the next 18 month's.
Low float means that stock will appreciate rapidly on rally of PHASE 11, and IND, Fast Track, and Orphan, DART wants NASDAQ listing, then Funds will be the vultures...only then too our advantage.
Playing very soothing music pre webcast...lol setting the mood!
type in browser [tpiv yahoo message] up comes Tapimmune then type on Tapimmune announces agreement to facilitate, scroll down and the link is there.
Blu
Conference call at 11 this morning...ASCO and other updates most likely then!
Blu
Don't forget TNBC.
Blu
Hoping that conference call has a Q and A, we'll be able to get some color on level of interest by what brokerage's, funds are listening. They will ask some direct questions that we could never get answers too.
Their first and foremost concern right now should be obtaining the up-listing to Nasdaq [raising cash position and share price]
I hope that it is, as the prices of their financings are ludicrous!
Catalyst in play, entry into Phase 11 announcement, Orphan, Fast Track and IND news in correlation, any type of partnership and possible grant funding.
Dart pretty much owns the company now, he dries up his selling, with the low float they could easily move this into $2 plus going into those catalyst's. I am presuming that is the plan go forward.
Blu
Sorry ash after rereading your post I think that was your take also, and I agree like a real Nasdaq company.
Actually ash, they have a conference call at 11 am this morning...this I don't want to miss [overall corporate update].
Blu
Ty, Canoe.
It's not.
I believe that Mayo was issued the patent [TNBC] not Tapimmune, they are in negotiations to finish the licence at this point, payments till have to be made.
Blu
tpizzazz24: In Tapimmune's press it states that Edith Perez is going to be the Lead Investigator on the TNBC Phase 11 trial, Fast Track, and Orphan Drug status initiated. Jacksonville site.
Blu
What I have garnered from looking at some of the ASCO results so far.
We seem to have one point that the market is just now catching on too that I have been mentioning all along. Although many companies are further along in trials...our technology has one proponent that others don't "COST". In reading many of the ASCO press on the larger companies in the same space it seems that all of them have the same problem "COST". Many of the drugs in their trials are going to cost Cancer victims $100,000 plus per year, that will be the difference. Our vaccine is a "Simple, Low Cost" injectable.
A company in the UK "ADAPTIMMUNE" was actually touted on the radio this morning coming out of the ASCO, my heart skipped a beat as until they announced that the company was out of the UK I thought it was Tapimmune. As it is they have literally copied our name. Upon further DD they also have T-Cell therapies to target and destroy cancer through what seems to be a similar Technology as ours. But they do not seem to be going after Breast, or TNBC only indication is in Ovarian.
They seem to be at relatively the same stage as us and their stock price is at $15...so that is a good gauge for us down the road.
I still believe that we will be an acquisition and "COST" is what is going to make us the company to beat, analyst touched on this when Glynn was talking last week, as cost is going to be the major factor in this space moving forward, not to mention we seem to have the superior platform at this point.
Quote from ASCO:
Treatment decisions are based on a hierarchy of factors. Drug effectiveness is considered to be the most important, followed by toxicity, and, lastly, cost. Yet, during the Saturday, May 30, Health Services Research and Quality of Care Oral Abstract Session, discussant Peter B. Bach, MD, of Memorial Sloan Kettering Cancer Center, asked, “Why treat prices as immutable? Would we really pay an infinite amount for a microscopic benefit?” A discussion of how cost does not necessarily reflect drug value, efforts to consider cost as part of the treatment decision, and methods to set new cancer drug prices based on value were the focus of the session.
Since 1965 when Medicare was created, the introductory cost of new cancer drugs has increased 100-fold to approximately $10,000 a month (adjusted to 2014 dollars). Older drugs also contribute to soaring costs; the price of imatinib has risen from less than $100 per day in 2004 to more than $200 in 2014. Meanwhile, the Centers for Medicare & Medicaid Services (CMS) began applying a value-based payment modifier for physician groups in 2015, under which payments will be determined by the quality of patient care balanced against the cost of care.
Blu
It's been valued like a penny stock because management has treated it as such. started with not doing DD and letting Michael Gardner extract millions of shares and giving them no services in return.
Then after an outrageous 1/100 R/S where everyone was wiped out, the stock came out at around $2 plus, another entity told them he was going to take the stock to NASDAQ, once again smoke and mirrors and the stock was driven down to .10 cents.
Then it seems management still had no takers and no faith in their own years of hard work, they gave up the company once again .20 financing, and have issued warrants approx. 70 mill up to a $1.50.
Love the science but management seems to have little clue as to how to manage their company.
Vultures know this and are acting accordingly, as each quarter goes by I am more and more worried that they will simply opt for the easy way out and R/S the stock once more to meet NASDAQ Reg's.
I am still a great advocate for the stock, but that is the nuts and bolts of it, as I have first hand experienced it. It is very frustrating to watch a company with such potential allow others to dictate their destiny.
Giving away the company for $1.50, no wonder they get no street cred!
Blu
I completely concur with you, manipulation at it's finest.
Buying back into it at .30 and up showing confidence, we should move up from here as you say...kind of like last kick at the can so to speak.
Blu
nartcr: Well usually when warrants are exercised [hence dilution], it is the norm for the price to decline, now they haven't made the announcement of the .40 exercise. And although the conference call was hard to understand [background noise, etc] he did make the comment that they had new financing based on the first, I took that too mean that the .40's had or were going to be exercised in the near term.
The fierce selling in the past 2 weeks I am crediting to taking profits on the .20's, then buying the .40's, it looks like over the past 2 weeks that there has been almost 7 mill shared sold, thus the stagnant price from .35 to .40.
Consolidation has really been quite good so far in the .40 to .36 range, looking for selling to dry up and stock building a new base between .40 and .50.
But remember the start of treatment of patients Glynnn said would be starting end of Q3.
Fast Track, Orphan status, IND, Phase 11, maybe grant funding nothing but positives in the near future, should be a whole new round of investors and cause price is higher and low float lets hope that the price moves higher easier.
Blu.
Sorry I took tomorrow too mean weekend, it is the weekend.
Blu
Sorry I took tomorrow as the weekend, its the weekend.
Few points on conference...
Glynn his typical reserved self.
1. T-Cell Therapeutics, Tapimmune will be best in class.
2. Industry threshold for various cancers usually measured at 40 to 50%, they are at 80/90% in various indications.
3. Finally letting us know that time to recurrence is "Long Lived", in the abstract but cannot be reiterated enough.
4. Sounding like they may have a corporate partner for Ovarian trial, milestone payments may be involved.
5. Treatment of patients starting in end of Q3, fast track and IND should be approved.
6. Sounds like the .40 warrants are being exercised soon, taking them well into Phase 11.
7. Herceptin patients have a typical relapse time of 24 months, Ovarian 18 months. Tapimmune has surpassed the 18 month recurrence point. Full data on that in next few weeks.
Overall no negatives, simple injection, and very low cost. when Phase 11 trials start, they should start getting a lot of attention. Looks like time to recurrence is strong, and should only accentuate with Polystart "Prime and Boost" combination therapy.
A true driver, as each 6 month's milestone passes, they are close to Herceptin now, [Glynn said 18 month's plus that is huge] 6 month's to a year they will have surpassed. Once again, potential of acquisition/buyout in next 18/24 months, simple and low cost massive driver.
RK: We are both working towards the same end, not telling you what you may or may not post, but Tapimmune's science is extremely complex. That few of us or even the medical community at large seem to really understand at this time.
If they did, the science and our stock would have been much better embraced at this point in time, time to recurrence is going to be a major piece of the puzzle going forward.
Hey it sounded good, got my attention.
Now for my interpretation, I believe that this is only the tip of the iceberg, as they apply their TAP technology, Polystart, Folate Receptor, numerous antigens and their Prime and Boost strategies together.
Their technology will become much more potent, right now it seems as if they are presenting much of their data independently, very hard for the medical and investment communities to fully digest it's full potential.
Any input with a sound foundation is welcomed.
If that's true, please don't post medical information that may or not apply to Tapimmune's science, I am not a novice [in equities]and very well versed in Tapimmune's science and management.
Comment may be misleading, unless you have factual data to back it up in regards to Tapimmunes science, if you have that I'm sure we would all like to see it.
Blu
RK; Thanks for that most insightful definition of the Treg's response, been with Tapimmune for years technology is sound. Fundamentals are clear, but the science is tough to disseminate at times. Are you in the field medically speaking?
Any further input in that regard highly appreciated...if you are a medical representative.
Blu
I'm Canadian never had a problem, know that you can't buy in TFSA, and some banks don't like penny stocks. At end of the day it's our call.
Blu
True, but what advantage would that present as we will just exercise at .70, maybe costing them approx, 2 to 3 mill more. if they wanted to help us them would leave maybe into .50 don't see much more than that.
Considering the upcoming data, and the fact that it is in their best interest to see stock much higher, a prudent move would be to exercise at .40.
Blu
Just an educated guess, but believe a lot of the resistance we have seen .30 and up, has been one of the warrant holders at .20, freeing up cash on that position. I expect them to exercise their .40 warrants soon, as to whether or not there will be a pullback maybe, maybe not,
Some dilution yes, but float is below most at this point so may be mute point, don't expect it to retrace much as the timing will coincide with data news.
With the low float as the price get's higher, won't be as many quick in and out traders as fewer will be able to buy large blocks, great for us. As stock may move higher, quicker, sellers after data should dry up somewhat also.
If full line of data is as good as predicted, should garner a whole new round of investors, and as price increases management should have an agenda to get it to the Nasdaq eligible range.
Our institutional investors know that is the key to unlocking the stocks true potential, and that point will be huge providing the data is good, as brokerage, and funds will finally be able to justify positions in clients accounts.
Hope you all are having a safe memorial weekend.
Blu
Would like to wish you all a great Memorial day weekend from Canada.
Blu
Investors have the option to exercise warrants at.40, why would they wait till .50? .60?
Or Tapimmune has the option to call warrants when strike price is .70 for something like 20 days.
Hope this helps
Blu
Hey Bio, $10 is my target also, although others may be skeptical of my predictions of an acquisition/buyout in 18 months to two years.
I believe it too be a real possibility, so you may not have to wait, I don't see any problems in the Phase 11 study as it already has proven out to be very safe and initial immune responses into the long term follow up still showed heightened immune response in 16 of 16 patients...very encouraging.
Who wouldn't want our multiple platforms to accentuate their own technologies, and I don't believe management would entertain anything below $10.
Having said that if the Phase 11 trial is going well, or we get news that the Phase 1 patients have no recurrence over the next 12/24 months that would be huge.
Sky is the limit then.
Blu
Tapimmune is not a one trick pony, they have multiple trials in multiple indications as I have stated in previous posts.
Read press out yesterday, so far everything has worked out as predicted, do your on DD on Keith Knutson, and Edith Perez.
They have the original TAP tech, Poly-start, then their 3 possible trials in 3 different indications maybe more.
16 of 16 had prolonged immune responses in long term follow up, mild to moderate reactions, no adverse affects as other's have experienced.
The large investors have seen data that we are not privy too, and have ponied up their cash, everything to "date' looks good the future is not predictable.
One of the world's most foremost Immunologist Perez [not to mention Keith] seems to think they are on too something, who are we to argue with that kind of endorsement.
Phase 1 only identifies safe and initial immune response.
Their combined platforms may be synergistic with many other diseases down the road, Poly-start which they are not allocating funds or time right now may be a big part of the puzzle.
They need to secure the licencing deals from Mayo right now [HER2/nue, Folate receptor, and TNBC], seems the platforms will only get stronger as trials continue.
Don't believe that Mayo itself or Perez would have made the comments they have if they have not gone over every possible negative aspect of the trial more than once.
We will know more next few weeks, months.
Blu
Hard to predict considering everyone has been waiting for these results, those of us that have been long term holders already knew the results were good.
We have ASCO 2 weeks away, great audience, many of who have been on the sidelines, full clinical data to be presented, may sway those who have been waiting for validation to get on board.
Looks like there has been buying/selling consolidation on the two moves up in the last 2 weeks, looks like most of trading today has been profit taking, building a base that hopefully will not retrace beyond .35.
In the next 3 months, digestion of data, wouldn't expect much selling from that as we are already far below peers. News should come out on Beginning of Phase 11 clinical trials, FDA fast track status and IND application. How many indications they are going to move forward with, TNBC, HER2/nue, Ovarian or all of the above.
Possible grant funding application accepted, and just an overall validation of the science at this point.
The ASCO meeting, and entry into Phase 11 on multiple indications
if compared to peers would be substantial, really will know much more after ASCO.
Remember the float is low, wouldn't anticipate much selling after ASCO and before start of Phase 11 as those events will surely be the turning point for the company.
I would hope that within 3 months the stock is in a range of .75 to a dollar, having said that if great news keeps coming out a company with multiple indications in billion dollar markets should command a much higher stock price.
Being on the OTC, I believe is their biggest hurdle right now, I hope that they are working feverishly on getting the market cap up, cash infusion by way of warrants and share price to at least $2.
I think there main focus after getting Phase 11 started is to share price above $2, and am speculating that they may get help in that regard from our big investors, who I am sure know we have to get off OTC.
Just an educated opinion, so I am of the $1 to $2 dollar in 3 to 6 months.
Blu
Hey ash: Are you referring to a possible retrace down, or PPS moving forward?
My postings are simply trying to help those of you that are here for lol "3 weeks", I am very well versed on what is happening behind the scenes. There are traders and long term holders each has own agenda and I wish all the best.
Just saying the catalyst's far out way what some may perceive as short term pennies, I am here to help if you would prefer I will sit on the sidelines and watch it play out.
Anyone interested may private message me, and I will respond to the best of my ability, I've been an investor way to long to get into petty squabbles...lol on a message board.
Been with the company 4 years plus hardly a novice in regards to everything going on...good luck also.
Let's put it this way it you held the warrants would you exercise at .40, or have us exercise at .70.